Tenaya Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Tenaya Therapeutics, Inc., a Delaware biotechnology company listed on Nasdaq under ticker TNYA, filed this Form 8-K on June 9, 2022, reporting the results of its annual meeting of stockholders held that day.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating performance, or other financial metrics.
Material Changes and Voting Results
- All four Class I director nominees were elected to serve until the 2025 annual meeting and until their successors are elected and qualified: David Goeddel, Ph.D.; Karah Parschauer, J.D.; Jeffrey T. Walsh, M.B.A.; and R. Sanders Williams, M.D.
- Votes for the nominees ranged from 34,063,079 to 34,833,578; broker non-votes totaled 829,857 for each nominee.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 35,984,423 votes for, 148 against, and 244 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no management guidance, business outlook, risk updates, contingencies, financing announcements, or unusual financial items. It identifies the company as an emerging growth company.
Key Facts to Verify
- Confirm the elected directors’ continued service and any subsequent changes to board composition.
- Confirm Deloitte & Touche LLP’s appointment for the fiscal year ending December 31, 2022.
- Review subsequent filings for financial results, financing activity, liquidity updates, or operational developments, none of which are included in this Form 8-K.